U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07000318) titled 'CS-206 in Patients With Sickle Cell Disease' on May 30.
Brief Summary: The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-206 injection in treating sickle cell disease.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease
Intervention:
GENETIC: CS-206
Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Children's Hospital of Fudan University
Disclaimer: Curated by HT Syndication....